Literature DB >> 1535455

Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes.

S Amigorena1, C Bonnerot, J R Drake, D Choquet, W Hunziker, J G Guillet, P Webster, C Sautes, I Mellman, W H Fridman.   

Abstract

B lymphocytes and macrophages express closely related immunoglobulin G (IgG) Fc receptors (Fc gamma RII) that differ only in the structures of their cytoplasmic domains. Because of cell type-specific alternative messenger RNA splicing, B-cell Fc gamma RII contains an insertion of 47 amino acids that participates in determining receptor function in these cells. Transfection of an Fc gamma RII-negative B-cell line with complementary DNA's encoding the two splice products and various receptor mutants indicated that the insertion was responsible for preventing both Fc gamma RII-mediated endocytosis and Fc gamma RII-mediated antigen presentation. The insertion was not required for Fc gamma RII to modulate surface immunoglobulin-triggered B-cell activation. Instead, regulation of activation involved a region of the cytoplasmic domain common to both the lymphocyte and macrophage receptor isoforms. In contrast, the insertion did contribute to the formation of caps in response to receptor cross-linking, consistent with suggestions that the lymphocyte but not macrophage form of the receptor can associate with the detergent-insoluble cytoskeleton.

Mesh:

Substances:

Year:  1992        PMID: 1535455     DOI: 10.1126/science.1535455

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  98 in total

1.  Early endosomes are required for major histocompatiblity complex class II transport to peptide-loading compartments.

Authors:  V Brachet; G Péhau-Arnaudet; C Desaymard; G Raposo; S Amigorena
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

Review 2.  ITAMs versus ITIMs: striking a balance during cell regulation.

Authors:  Daniel D Billadeau; Paul J Leibson
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 3.  Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.

Authors:  S Izui; L Fossati-Jimack; S A da Silveira; T Moll
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 4.  Positive and negative roles of CD72 in B cell function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice.

Authors:  M C Karlsson; S Wernersson; T Diaz de Ståhl; S Gustavsson; B Heyman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 6.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

7.  Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.

Authors:  Jessica L Rastad; William R Green
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

8.  Recruitment of Rab27a to phagosomes controls microbial antigen cross-presentation by dendritic cells.

Authors:  Seong Hyun Kim; Annelies Visser; Carin Cruijsen; Adrianus W M van der Velden; Marianne Boes
Journal:  Infect Immun       Date:  2008-09-08       Impact factor: 3.441

9.  FcgammaRIa-gamma-chain complexes trigger antibody-dependent cell-mediated cytotoxicity (ADCC) in CD5+ B cell/macrophage IIA1.6 cells.

Authors:  M J Van Vugt; I E Van den Herik-Oudijk; J G Van de Winkel
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

10.  Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis.

Authors:  Anja S Mühlfeld; Stephan Segerer; Kelly Hudkins; Matthew D Carling; Min Wen; Andrew G Farr; Jeffrey V Ravetch; Charles E Alpers
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.